Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled A RANDOMIZED, 2-ARM, ...

There was no difference in risk for lenalidomide plus cyclophosphamide, lenalidomide plus dexamethasone, and melphalan alone. "These data suggest that the future role of oral melphalan in ...

Contacts IR Contacts United States Ran Meir (267) 468-4475 Israel Yael Ashman 972 (3) 914-8262 PR Contacts United States Kelley Dougherty (973) 658-0237 Yonatan Beker (973) 264 7378 ...

A dose-adjusted lenalidomide regimen that included discontinuation of dexamethasone after 9 months appeared safe and led to similar outcomes as continuous lenalidomide plus dexamethasone among ...

1 Belada D, M.D., Ph.D., et al. A Phase 1b, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in ...

"Lenalidomide maintenance following autologous stem cell transplant can now be considered a standard of care for people with multiple myeloma," says Dr. McCarthy, senior author on the meta ...

The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly diagnosed diffuse large B-cell lymphoma, according to study results published in Journal of ...

Mayo Clinic. "Lenalidomide may delay onset of myeloma-related bone, organ damage." ScienceDaily. ScienceDaily, 28 October 2019. <www.sciencedaily.com / releases / 2019 / 10 / 191028104212.htm>.

Lenalidomide is being evaluated in a number of adult solid tumors, including lymphomas, 8 renal cell carcinoma, 9 melanoma, and CNS tumors. 10 Although the exact antitumor mechanism is not completely ...

Monjuvi is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL ...